Sort the four drugs into the two fundamental categories of osteoporosis treatment. The antiresorptive camp works by shutting down osteoclasts so that existing bone is not broken down: this includes the bisphosphonates alendronate and etidronate, which bind hydroxyapatite and poison osteoclast function, and strontium, which is conventionally placed with the antiresorptives for its osteoclast-suppressing component. All three therefore decrease bone resorption. The odd drug out is teriparatide, a fragment of parathyroid hormone administered as once-daily injections. Although chronically high PTH dissolves bone, the intermittent low-dose pulse delivered by teriparatide flips the effect and powerfully stimulates osteoblasts, making it an anabolic, bone-forming agent rather than a resorption blocker. Since the stem asks which drug does not reduce resorption, the formation-stimulating PTH analogue is the answer. \[\boxed{\text{Teriparatide}}\]